Carmel Diagnostics is a healthcare startup that develops clinical applications of its proprietary platform, Thermochemi luminescence (TCL) technology. TCL enables assessment of oxidative stress in various body fluids. The lead product "Fertissimo" is a powerful point-of-care diagnostic system that rapidly highlights the most viable embryos to conceive in IVF-induced pregnancy, using oxidative stress as a biomarker. Samples are automatically processed to provide a quantitative score for achieving pregnancy. Carmel has an experienced management team and strong IP portfolio.